Diagnosing heart failure with preserved ejection fraction

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 5, 2013, Pages 463-474

  Becher, Peter Moritz ^a   Lindner, Diana ^a   Fluschnik, Nina ^a   Blankenberg, Stefan ^a   Westermann, Dirk ^a  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

Author keywords

Diagnosis; Diastolic; Heart failure; Preserved ejection fraction

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; MINERALOCORTICOID RECEPTOR; NATRIURETIC PEPTIDE TYPE C; SILDENAFIL; SPIRONOLACTONE; URODILATIN;

ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; DIASTOLIC DYSFUNCTION; DOPPLER ECHO; DYSPNEA; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; EXERCISE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERVOLEMIA; PATHOPHYSIOLOGY; POTASSIUM DEPLETION; PULMONARY ARTERY OCCLUSION PRESSURE; TISSUE DOPPLER IMAGING; VASCULITIS; HEART FAILURE; HEART FUNCTION TEST; HEART STROKE VOLUME; PHYSIOLOGY;

HEART FAILURE; HEART FUNCTION TESTS; HUMANS; STROKE VOLUME;

EID: 84883190827     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2013.825246     Document Type: Article

References (81)

1. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-9
2. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognosis of heart failure with preserved ejection fraction: A 5 year prospective population-based study. Eur Heart J 2008;29:339-47
3. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment. Eur Heart J 2011;32:670-9
4. Tiller D, Russ M, Greiser KH, et al. Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study. PLoS ONE 2013;8:e59225
5. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350:1953-9
6. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45
7. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-preserved trial. Lancet 2003;362:777-81
8. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-67
9. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 2013;309:781-91
10. Daniel KR, Wells G, Stewart K, et al. Effect of aldosterone antagonism on exercise tolerance, doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail 2009;15:68-74
11. Bernal J, Pitta SR, Thatai D. Role of the renin-angiotensin-aldosterone system in diastolic heart failure: Potential for pharmacologic intervention. Am J Cardiovasc Drugs 2006;6:373-81
12. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 2013;309:1268-77
13. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-50
14. Heymans S, Hirsch E, Anker SD, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009;11:119-29
15. Westermann D, Kasner M, Steendijk P, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008;117:2051-60
16. Gillebert TC, De Pauw M, Timmermans F. Echo-doppler assessment of diastole: Flow, function and haemodynamics. Heart 2013;99:55-64
17. From AM, Borlaug BA. Heart failure with preserved ejection fraction: Pathophysiology and emerging therapies. Cardiovasc Ther 2011;29:e6-21
18. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association( HFA) of the ESC. Eur J Heart Fail 2012;14:803-69
19. Leong DP, De Pasquale CG, Selvanayagam JB. Heart failure with normal ejection fraction: The complementary roles of echocardiography and CMR imaging. JACC Cardiovasc Imaging 2010;3:409-20
20. Prasad A, Hastings JL, Shibata S, et al. Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart Fail 2010;3:617-26
21. Cannan C, Friedrich MG. Cardiac magnetic resonance imaging: Current status and future directions. Expert Rev Cardiovasc Ther 2010;8:1175-89
22. Cea LB. Natriuretic peptide family: New aspects. Curr Med Chem Cardiovasc Hematol Agents 2005;3:87-98
23. Michels P, Tarnow J. Natriuretic peptides: Physiological, pathophysiological and clinical aspects. Anasthesiol Intensivmed Notfallmed Schmerzther 2001;36:406-16
24. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology 1993;132:1961-70
25. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986;78:1362-74
26. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-9
27. Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NTPROBNP): A new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287-96
28. van Veldhuisen DJ, Linssen GC, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013;61:1498-506
29. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90
30. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:e1-194
31. Gorcsan J III. Echocardiographic strain imaging for myocardial viability: An improvement over visual assessment? Circulation 2005;112:3820-2
32. Gorcsan J III, Tanaka H. Echocardiographic assessment of myocardial strain. J Am Coll Cardiol 2011;58:1401-13
33. Ohtani T, Mohammed SF, Yamamoto K, et al. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. Eur Heart J 2012 33 1742-1749
34. Ducas R, Tsang W, Chong AA, et al. Echocardiography and vascular ultrasound: New developments and future directions. Can J Cardiol 2013;29:304-16
35. Amundsen BH, Helle-Valle T, Edvardsen T, et al. Noninvasive myocardial strain measurement by speckle tracking echocardiography: Validation against sonomicrometry and tagged magnetic resonance imaging. J Am Coll Cardiol 2006;47:789-93
36. Korinek J, Wang J, Sengupta PP, et al. Two-dimensional strain-a doppler-independent ultrasound method for quantitation of regional deformation: Validation in vitro and in vivo. J Am Soc Echocardiogr 2005;18:1247-53
37. Helle-Valle T, Crosby J, Edvardsen T, et al. New noninvasive method for assessment of left ventricular rotation: Speckle tracking echocardiography. Circulation 2005;112:3149-56
38. Kalogeropoulos AP, Georgiopoulou VV, Howell S, et al. Evaluation of right intraventricular dyssynchrony by two-dimensional strain echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr 2008;21:1028-34
39. Yip GW, Frenneaux M, Sanderson JE. Heart failure with a normal ejection fraction: New developments. Heart 2009;95:1549-52
40. Tan YT, Wenzelburger F, Lee E, et al. The pathophysiology of heart failure with normal ejection fraction: Exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol 2009;54:36-46
41. Borlaug BA, Lam CS, Roger VL, et al. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009;54:410-18
42. Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011;4:44-52
43. van Heerebeek L, Somsen A, Paulus WJ. The failing diabetic heart: Focus on diastolic left ventricular dysfunction. Curr Diab Rep 2009;9:79-86
44. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000;86:494-501
45. Tschope C, Bock CT, Kasner M, et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005;111:879-86
46. Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010;56:845-54
47. Akiyama E, Sugiyama S, Matsuzawa Y, et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2012;60:1778-86
48. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9
49. Kawaguchi M, Hay I, Fetics B, et al. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations. Circulation 2003;107:714-20
50. Gillebert TC, Leite-Moreira AF, De Hert SG. Load dependent diastolic dysfunction in heart failure. Heart Fail Rev 2000;5:345-55
51. Borlaug BA, Melenovsky V, Redfield MM, et al. Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol 2007;50:1570-7
52. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study. J Am Coll Cardiol 2009;53:1119-26
53. Lam CS, Borlaug BA, Kane GC, et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009;119:2663-70
54. Ohara T, Ohte N, Little WC. Pulmonary hypertension in heart failure with preserved left ventricular ejection fraction: Diagnosis and management. Curr Opin Cardiol 2012;27:281-7
55. Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010;3:588-95
56. Borlaug BA, Jaber WA, Ommen SR, et al. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 2011;97:964-9
57. Kasner M, Westermann D, Steendijk P, et al. Left ventricular dysfunction induced by nonsevere idiopathic pulmonary arterial hypertension: A pressure-volume relationship study. Am J Respir Crit Care Med 2012;186:181-9
58. Ennezat PV, Lefetz Y, Marechaux S, et al. Left ventricular abnormal response during dynamic exercise in patients with heart failure and preserved left ventricular ejection fraction at rest. J Card Fail 2008;14:475-80
59. Brubaker PH, Joo KC, Stewart KP, et al. Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. J Cardiopulm Rehabil 2006;26:86-9
60. Higginbotham MB, Morris KG, Williams RS, et al. Regulation of stroke volume during submaximal and maximal upright exercise in normal man. Circ Res 1986;58:281-91
61. Abudiab MM, Redfield MM, Melenovsky V, et al. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail 2013;15(7):776-85
62. Zile MR, Kjellstrom B, Bennett T, et al. Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circ Heart Fail 2013;6(3):508-16
63. Penicka M, Bartunek J, Trakalova H, et al. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: A pressure-volume loop analysis. J Am Coll Cardiol 2010;55:1701-10
64. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-33
65. Gharacholou SM, Scott CG, Takahashi PY, et al. Left ventricular diastolic function and long-term outcomes in patients with normal exercise echocardiographic findings. Am J Cardiol 2013;112(2):200-7
66. Kempf T, Horn-Wichmann R, Brabant G, et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 2007;53:284-91
67. Stahrenberg R, Edelmann F, Mende M, et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 2010;12:1309-16
68. Santhanakrishnan R, Chong JP, Ng TP, et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012;14:1338-47
69. Dumic J, Dabelic S, Flogel M. Galectin- 3: An open-ended story. Biochim Biophys Acta 2006;1760:616-35
70. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60-8
71. Carrasco-Sanchez FJ, Galisteo-Almeda L, Paez-Rubio I, et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail 2011;17:31-8
72. Dinh W, Futh R, Nickl W, et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol 2009;8:58
73. Zibadi S, Vazquez R, Larson DF, et al. T lymphocyte regulation of lysyl oxidase in diet-induced cardiac fibrosis. Cardiovasc Toxicol 2010;10:190-8
74. Zile MR, Baicu CF. Biomarkers of diastolic dysfunction and myocardial fibrosis: Application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res 2013;6(4):501-15
75. Melendez GC, McLarty JL, Levick SP, et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010;56:225-31
76. Moldoveanu E, Serban M, Marta DS, et al. Lipoprotein-associated phospholipase A2 activity in patients with preserved left ventricular ejection fraction. Biomarkers 2011;16:587-9
77. Bishu K, Deswal A, Chen HH, et al. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J 2012;164:763-70.e3
78. Manzano L, Babalis D, Roughton M, et al. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail 2011;13:528-36
79. Nair N, Kumar S, Gongora E, et al. Circulating miRNA as novel markers for diastolic dysfunction. Mol Cell Biochem 2013;376:33-40
80. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet 2010;3:484-8
81. Bauersachs J, Thum T. Biogenesis and regulation of cardiovascular microRNAs. Circ Res 2011;109:334-47